Healthcare
LAV leads $50m Series B for China's Lynk Pharma
Lilly Asia Ventures (LAV) has led a $50 million Series B round for Lynk Pharmaceuticals, a China-based drug developer that focuses on small-molecule treatments for autoimmune disease, inflammation, and cancer.
China cancer treatment specialist Ionova raises $100m
Tsing Song Capital, a Chinese healthcare-focused private equity firm, has led a $100 million round for Ionova Life Science, a local biotech player specializing in cancer treatments.
CBC-led consortium buys Bain's stake in Korean botox maker
A consortium led by Asia healthcare-focused private equity firm CBC Group has agreed to acquire a 46.9% interest in Hugel, a South Korean manufacturer of botox and other health-related pharmaceuticals, for KRW1.7 trillion ($1.5 billion).
BGH-owned Abano to buy Australia dentistry business
Abano Healthcare, a New Zealand dentistry chain owned by BGH Capital and Ontario Teachers’ Pension Plan (OTPP), has agreed to acquire Australian peer 1300 Smiles for an enterprise valuation of A$165 million ($120 million).
China vaccine developer Abogen raises $700m
Suzhou Abogen Biosciences, a Chinese vaccine developer targeting COVID-19, has raised $700 million in Series C funding featuring Temasek Holdings, Loyal Valley Capital, and Lilly Asia Ventures.
Inspiration Capital hits first close on debut China fund
Inspiration Capital Partners, a China-focused private equity firm established by investment professionals from Vivo Capital and Goldman Sachs, has reached a first close of approximately $65 million on its debut US dollar-denominated fund.
Chinese AI diagnosis player Shukun raises $108m
Shukun, a Chinese developer of artificial intelligence (AI) technology used in medical imaging diagnosis, has raised RMB700 million ($108 million) from Goldman Sachs, Primavera Capital Group, Sequoia Capital China, Marathon Venture Partners, and Sage...
Boyu, Janchor back China medical finance start-up
MediTrust Health, China-based healthcare payments and insurance platform, has raised RMB2 billion ($309 million) in Series C funding led by Boyu Capital and Janchor Partners.
Baring acquires Hinduja healthcare business for $1.2b
Baring Private Equity Asia has agreed to buy a healthcare services unit of Anglo-Indian conglomerate Hinduja Group at an enterprise valuation of $1.2 billion.
China's Miaoshou Doctor raises $231m Series F
Beijing Yuanxin Technology, operator of China-based online healthcare services platform Miaoshou Doctor, has raised RMB1.5 billion ($231 million) in Series F funding featuring Sequoia Capital China.
Affinity exits Australia healthcare software business
Affinity Equity Partners has agreed to sell MedicalDirector, an Australia-based clinic management software developer, to Telstra Health for an enterprise valuation of A$350 million ($257 million).
CPE leads $150m Series B for China CDMO
Joinn Biologics, a China-based contract development and manufacturing organization (CDMO), has raised $150 million in Series B funding led by CPE.
China cancer screening specialist raises $99m
China Merchants Capital has led a $99.5 million funding round for Berry Oncology Corporation, an early cancer screening spin-out from China-based genetic testing specialist Berry Genomics.
China AI drug developer BioMap raises $100m
GGV Capital has led a $100 million Series A round for BioMap, a China-based biological computing platform. It marks the first time the company has sought external funding.
China's Vitalbridge reaches $200m first close on Fund II
Vitalbridge Capital, a China-based venture capital firm that spun out from Trustbridge Partners, has achieved a first close of $200 million on its second US dollar-denominated fund.
Sequoia China leads $100m Series B for Bota Biosciences
Sequoia Capital China had led a $100 million Series B round for Bota Biosciences, a China-based biotech company that has developed a next-generation platform for manufacturing high-performing industrial compounds.
NewQuest buys secondary position in India hospital chain
Direct secondaries specialist NewQuest Capital Partners has acquired a minority stake in Cloudnine, an India-based hospital chain, by committing primary capital and taking out several existing investors.
CPE joins Series D for China biotech player TransThera
TransThera, a China-based drug developer, has raised $100 million in Series D funding led by CPE and China Structural Reform Fund.
PAG acquires Indian CDMO Acme for $145m
PAG has acquired a controlling stake in Acme Formulation Private, an India-based contract development and manufacturing organization (CDMO), for approximately $145 million.
China DNA sequencing start-up gets $116m Series C
Chinese next-generation sequencing (NGS) player Geneplus Technology has raised a RMB750 million ($116 million) Series C round led by China Construction Bank’s venture unit CCB International.
Hong Kong sees rush of VC-backed biotech IPO filings
Five VC-backed pre-revenue Chinese biotech companies have filed to list in Hong Kong over the past two weeks, doubling the size of the IPO pipeline in this category.
India's HealthifyMe closes $75m Series C
LeapFrong Investments and Khosla Ventures have led a $75 million Series C round for HealthifyMe, a mobile health and fitness app operator with a presence in India and Southeast Asia.
China beauty: Service with a smile
Beauty and wellness are at the vanguard of China’s fast-rising services sector. Investors see clear paths to growth, but size presents a plethora of problems in terms of standardizing service quality
China's Meiwei Dental raises $150m
China’s Meiwei Dental Group has raised a RMB1 billion ($150 million) Series B round from Fortune Capital, TFTR Investment, and local conglomerate New Hope Group.